Neurologic adverse events following influenza A (H1N1) vaccinations in children
Related Experiment Video
Updated: May 25, 2026

A Luciferase-fluorescent Reporter Influenza Virus for Live Imaging and Quantification of Viral Infection
Published on: August 14, 2019
Seung Jae Lee1, Young Ok Kim, Young Jong Woo
1Department of Pediatrics, School of Medicine, Chonnam National University, Gwangju, Korea.
Insights
Pediatric neurologic adverse events (NAE) following the H1N1 vaccine were primarily motor weakness from polyneuropathy. Most children recovered fully within months, showing good prognosis for post-vaccine H1N1 neuropathy.
Area of Science:
- Neurology
- Vaccinology
- Pediatrics
Background:
- Limited pediatric data exists on neurologic adverse events (NAE) post-monovalent pandemic influenza A (H1N1) vaccination.
- Guillain-Barré syndrome is a rare but serious potential NAE.
- Understanding pediatric NAE is crucial for vaccine safety monitoring.
Purpose of the Study:
- To review pediatric NAE data following H1N1 vaccination.
- To analyze the clinical course and outcomes of children with peripheral neuropathy after H1N1 vaccination.
Main Methods:
- Retrospective review of 14 pediatric cases with NAE post-H1N1 vaccination.
- Single-center study at Chonnam National University Hospital (November 2009 - March 2010).
- Assessment of clinical diagnoses and follow-up for patients with peripheral neuropathy.
Main Results:
- Polyneuropathy was the most common NAE (78.6%), presenting as motor weakness.
- Peripheral neuropathy diagnosed in 92.9% of cases (13/14).
- Two patients met criteria for Guillain-Barré syndrome (Level 3 certainty).
Conclusions:
- Post-vaccine NAE were predominantly motor weakness due to polyneuropathy.
- Complete recovery occurred within months without long-term sequelae.
- H1N1 vaccination in children showed a generally good prognosis for NAE.
Background:
Since the monovalent pandemic influenza A (H1N1) vaccine was recommended worldwide in October 2009, there has been a shortage of pediatric clinical data for post-vaccine neurologic adverse events (NAE), including Guillain-Barré syndrome. We reviewed pediatric NAE data following H1N1 vaccinations and for patients with peripheral neuropathy, we followed their progress.
Methods:
In our single-center study, we retrospectively reviewed 14 cases of children who visited the Division of Pediatric Neurology in the Department of Pediatrics of Chonnam National University Hospital due to NAE following monovalent influenza A (H1N1) vaccination between November 2009 and March 2010.
Results:
Clinical diagnoses for major NAE included: polyneuropathy in the extremities (11/14, 78.6%), sensory mononeuropathy with numbness in the left fibula area (1/14, 7.1%), Bell's palsy (1/14, 7.1%) and recent-onset acute headache only (1/14, 7.1%). Therefore, most patients were diagnosed as having peripheral neuropathy (13/14, 92.9%), and two met the Brighton Collaboration Guillain-Barré syndrome definition criteria for level 3 (the lowest level of diagnostic certainty).
Conclusions:
Post-vaccine NAE were mainly motor weakness due to polyneuropathy, which had a good prognosis of complete improvement within a few months without sequelae.
Related Concept Videos
Influenza
Vaccinations
Encephalitis l: Introduction
Diphtheria
Local Anesthetics: Adverse Effects
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
Arboviral Encephalitis

